Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

ATP-based tumor chemosensitivity testing: assisting new agent development.

I A Cree1, C M Kurbacher

  • 1Department of Pathology, Institute of Ophthalmology, University College London, UK. i.cree@ucl.ac.uk

Anti-Cancer Drugs
|September 7, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

WHO 2022 classification of penile and scrotal cancers: updates and evolution.

Histopathology·2022
Same author

Targeting EGFR and PI3K pathways in ovarian cancer.

British journal of cancer·2013
Same author

Identification of markers of prostate cancer progression using candidate gene expression.

British journal of cancer·2011
Same author

Circulating tumour markers can define patients with normal colons, benign polyps, and cancers.

British journal of cancer·2011
Same author

Molecular basis of chemosensitivity of platinum pre-treated ovarian cancer to chemotherapy.

British journal of cancer·2010
Same author

Measurement of cytotoxicity by ATP-based luminescence assay in primary cell cultures and cell lines.

Toxicology in vitro : an international journal published in association with BIBRA·2010
Same journal

Akt inhibitor-IV in estrogen receptor-positive breast cancer cells: cytotoxic, apoptotic, transcriptional, and in-silico comparison with tamoxifen.

Anti-cancer drugs·2026
Same journal

Prolonged multimodal disease control with trifluridine/tipiracil plus bevacizumab in KRAS-mutant metastatic rectal cancer: a case report.

Anti-cancer drugs·2026
Same journal

Growth differentiation factor-11 inhibits the progression of acute myeloid leukemia and increases chemosensitivity by inhibiting cathepsin S.

Anti-cancer drugs·2026
Same journal

Inavolisib and lenvatinib for PIK3CA-mutated refractory splenic angiosarcoma: a case report.

Anti-cancer drugs·2026
Same journal

Drug repurposing of liver cancer based on multimodal neural network and virtual screening.

Anti-cancer drugs·2026
Same journal

Discovery of an orally active and liver-targeted dual prodrug of 5-fluoro-2'-deoxyuridine-5'-monophosphate for the treatment of hepatocellular carcinoma.

Anti-cancer drugs·2026
See all related articles

Introducing new cancer chemotherapy agents is challenging due to extensive clinical trial requirements. An ex vivo chemosensitivity assay using patient tumor cells can streamline drug testing, reducing costs and accelerating the introduction of novel cancer treatments.

Area of Science:

  • Oncology
  • Pharmacology
  • Cancer Research

Background:

  • Cytotoxic chemotherapy has significantly advanced cancer treatment, with drug combinations widely used.
  • The introduction of new chemotherapy agents is hindered by the extensive and costly clinical trial process.
  • Molecular advancements in cancer biology are driving the development of novel therapeutic agents.

Purpose of the Study:

  • To explore a novel approach for efficiently introducing new chemotherapy agents into clinical practice.
  • To reduce the time and cost associated with the development and approval of new cancer drugs.
  • To optimize the use of novel agents by pre-clinically assessing their efficacy in patient-derived tumors.

Main Methods:

  • Utilizing an ATP-based chemosensitivity assay to test drug efficacy on patient tumor cells ex vivo.

Related Experiment Videos

  • Mimicking in vivo tumor conditions to accurately assess dose-response, sequence, and timing of chemotherapeutic agents.
  • Employing assays that allow for testing numerous drug combinations with limited patient samples.

    • Main Results:

    • The ex vivo chemosensitivity assay accurately models tumor environments, enabling detailed drug evaluation.
    • This method allows for the testing of many drug permutations, identifying optimal combinations.
    • The approach facilitates the selection of promising drug combinations for subsequent, more focused clinical trials.

    Conclusions:

    • Ex vivo chemosensitivity assays offer a viable strategy to overcome barriers in introducing new chemotherapy agents.
    • This method can significantly reduce the number of required phase II/III trials, saving time and resources.
    • Accelerated introduction of novel agents through pre-clinical ex vivo testing can benefit cancer patients sooner.